Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formebolone is a synthetic anabolic-androgenic steroid (AAS) derived from androstane. It is orally active and has been used as an anticatabolic and anabolic agent, particularly in the treatment of growth retardation and to increase bone mass. Its mechanism of action involves binding to androgen receptors in muscle and bone tissues, which stimulates protein synthesis and promotes muscle hypertrophy. Additionally, formebolone exhibits antiglucocorticoid activity by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 1, thereby reducing cortisol-mediated catabolism. It has been marketed under various brand names in Spain and Italy but is now classified as a prohibited substance by the World Anti-Doping Agency due to its potential for misuse in sports[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on formebolone.